Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from CinCor Pharma

AstraZeneca Stock Nabs Brief Breakout After $1.8 Billion CinCor Buyout

AstraZeneca stock briefly broke out on Tuesday, a day after announcing its $1.8 billion plan to acquire CinCor.

Investors Business Daily

AstraZeneca To Acquire Blood-Pressure Drugmaker In $1.8 Billion Deal

AstraZeneca To Acquire Blood-Pressure Drugmaker In $1.8 Billion Deal

AstraZeneca said it has agreed to buy CinCor Pharma, maker of clinical-stage blood pressure drug baxdrostat, in a deal valued at $1.8 billion.

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

$18 Million Bet On This Biotechnology Stock? 4 Stocks Insiders Are Buying

Although US stocks closed lower on Wednesday following the release of Fed minutes, there were a few notable insider trades.

Insiders Buy Around $70M Of 4 Stocks: Six Flags Entertainment, MGM Resorts And More

Although US stocks closed higher on Monday, there were a few notable insider trades.

12 Health Care Stocks Moving In Monday's Intraday Session

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

inkl

Read news from The Economist, FT, and more,
with one subscription

CinCor Pharma Begins Patient Dosing In Midstage Hypertension, Kidney Disease Study

CinCor Pharma Begins Patient Dosing In Midstage Hypertension, Kidney Disease Study

CinCor Pharma (NASDAQ: CINC) has dosed first patient in the figHTN-CKD Phase 2 clinical study of its drug candidate Baxdrostat (CIN-107) for the treatment of patients with uncontrolled hypertension and chronic kidney disease (CKD).

CinCor Pharma Q4 2021 Earnings Conference Call On March 22, 2022 At 08:30 AM ET

CinCor Pharma Q4 2021 Earnings Conference Call On March 22, 2022 At 08:30 AM ET

CinCor Pharma (NASDAQ:CINC) will host a conference call at 08:30 AM ET on March 22, 2022, to discuss Q4 2021 earnings results.

CinCor Pharma's Ex-Dividend Date Is Sunday, Here's What You Need To Know

CinCor Pharma's Ex-Dividend Date Is Sunday, Here's What You Need To Know

Sunday marks the last chance for investors to receive the next dividend payout from CinCor Pharma.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

European Commission

United Parcel Service

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Sickle Cell Disease

Ulcerative Colitis

Macular Degeneration

Amyotrophic lateral sclerosis

Places

251,598 stories

104,572 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play